lentiviral gene therapy (SR-TIGET/Bioverativ)

N/A

Report date: 2025/01/26 19:10:20

Base Information

Drug Namelentiviral gene therapy (SR-TIGET/Bioverativ)

Drug Alias NameLV.coFVIII.XTENlentiviral gene therapy (San Raffaele Telethon Institute/Biogen)lentiviral gene therapy (San Raffaele Telethon Institute/Biogen Idec)LV-FVIIIXTEN

ClassificationBiologics

Mechanisms of ActionCoagulation factor VIII stimulants

TargetsCoagulation factor VIII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItaly

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe San Raffaele Telethon Institute For Gene Therapy

China Registration ClassN/A

Develop Information

Active CompaniesThe San Raffaele Telethon Institute For Gene Therapy Bioverativ Inc

Inactive CompaniesBiogen Inc

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A